Leave a Reply

Your email address will not be published. Required fields are marked *

Next Post

FDA Approves Nucala for Hypereosinophilic Syndrome

Thu Oct 1 , 2020
TUESDAY, Sept. 29, 2020 (HealthDay News) The U.S. Food and Drug Administration announced the approval last week of the first treatment for hypereosinophilic syndrome (HES) in more than a decade. The drug, Nucala (mepolizumab), is approved for patients 12 years and older with HES for at least six months without […]

You May Like

Breaking News

Recent Posts